We are live on
!
Find out more
RI
RTW Investments Portfolio holdings
AUM
$10B
1-Year Est. Return
135.35%
This Fund
S&P 500
This Quarter
Est. Return
+30.89%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$331M
AUM Growth
+$38.2M
(+13%)
Cap. Flow
-$22.9M
Cap. Flow
% of AUM
-6.92%
Top 10 Holdings %
Top 10 Hldgs %
73.74%
Holding
44
New
9
Increased
8
Reduced
11
Closed
8
Top Buys
| 1 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$13.3M |
| 2 |
AGEN
Agenus
AGEN
|
+$10M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
+$8.17M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
+$7.86M |
| 5 |
Arrowhead Research
ARWR
|
+$7.24M |
Top Sells
| 1 |
BLUE
bluebird bio
BLUE
|
+$29.3M |
| 2 |
Incyte
INCY
|
+$16.9M |
| 3 |
KITE
Kite Pharma, Inc.
KITE
|
+$14.3M |
| 4 |
SSRG
SYMMETRY SURGICAL INC COMMON STK
SSRG
|
+$12.1M |
| 5 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$6.25M |
Sector Composition
| 1 | Healthcare | 90.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Alnylam Pharmaceuticals
ALNY
$37.8B
| $64.3M | 19.43% |
948,286
+115,737
| +14% | +$8.17M |
|
|
AVXS
2
DELISTED
AveXis, Inc. Common Stock
AVXS
| $34M | 10.29% |
825,980
+349,613
| +73% | +$13.3M |
|
|
AGEN
3
Agenus
AGEN
$208M
| $29.7M | 8.99% |
211,017
+87,252
| +70% | +$10M |
|
|
LJPC
4
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $27.8M | 8.41% |
1,170,151
-5,995
| -0.5% | -$113K |
|
|
5
BioCryst Pharmaceuticals
BCRX
$2.32B
| $18.5M | 5.6% |
4,204,579
+1,967,513
| +88% | +$7.86M |
|
|
6
Incyte
INCY
$23.3B
| $18M | 5.45% |
191,151
-201,085
| -51% | -$16.9M |
|
|
ACHN
7
DELISTED
Achillion Pharmaceuticals
ACHN
| $17.9M | 5.41% |
2,208,749
-215,387
| -9% | -$1.83M |
|
|
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $11.9M | 3.6% |
2,026,894
| – | – |
|
9
Bristol-Myers Squibb
BMY
$124B
| $11.3M | 3.42% |
209,701
| – | – |
|
10
SPDR Gold Trust
GLD
$129B
| $10.4M | 3.15% |
83,000
| – | – |
|
11
Atara Biotherapeutics
ATRA
$78.6M
| $9.8M | 2.96% |
18,325
-310
| -2% | -$168K |
|
|
12
Arrowhead Research
ARWR
$10.1B
| $8.21M | 2.48% |
+1,116,777
| New | +$7.24M |
|
13
Heron Therapeutics
HRTX
$90.1M
| $6.66M | 2.01% |
+386,787
| New | +$7.18M |
|
|
VIVE
14
DELISTED
VIVEVE MED INC
VIVE
| $6.06M | 1.83% |
839
+24
| +3% | +$159K |
|
|
BLUE
15
DELISTED
bluebird bio
BLUE
| $5.95M | 1.8% |
6,773
-40,475
| -86% | -$29.3M |
|
|
CORI
16
DELISTED
Corium International, Inc.
CORI
| $5.89M | 1.78% |
1,045,747
+192,786
| +23% | +$969K |
|
|
IVTY
17
DELISTED
Invuity, Inc
IVTY
| $5.39M | 1.63% |
392,838
+166,796
| +74% | +$1.98M |
|
18
Celldex Therapeutics
CLDX
$2.78B
| $5.02M | 1.52% |
82,878
-1,404
| -2% | -$87.4K |
|
|
MDCO
19
DELISTED
Medicines Co
MDCO
| $4.64M | 1.4% |
+123,000
| New | +$4.64M |
|
20
Omeros
OMER
$667M
| $4.27M | 1.29% |
383,012
-143,776
| -27% | -$1.64M |
|
21
Tactile Systems Technology
TCMD
$663M
| $4.26M | 1.29% |
+227,599
| New | +$3.49M |
|
|
JO
22
DELISTED
iPath Bloomberg Coffee Subindex Total Return ETN due June 24, 2038
JO
| $4.02M | 1.21% |
180,500
+36,300
| +25% | +$792K |
|
23
Regenxbio
RGNX
$579M
| $3.35M | 1.01% |
238,740
-4,044
| -2% | -$44.6K |
|
|
OXFD
24
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $2.96M | 0.9% |
+235,900
| New | +$2.37M |
|
|
FPRX
25
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $2.31M | 0.7% |
44,044
-657
| -1% | -$31.4K |
|
Similar funds
BEI
MG
LWCFA
HRCM
RA
VNIM
OAM
GI